Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.12 USD
Change Today +0.355 / 1.08%
Volume 58.4K
EBS On Other Exchanges
New York
As of 1:16 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $34.50
52 Week Low
10/15/14 - $19.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,280 Employees
Last Reported Date: 03/9/15
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.2M
Founder, Executive Chairman, Chairman of Stra...
Total Annual Compensation: $881.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $659.5K
Executive Vice President and President of Bio...
Total Annual Compensation: $623.1K
Executive Vice President and President of Bio...
Total Annual Compensation: $558.7K
Compensation as of Fiscal Year 2014.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions Wins $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies

Emergent BioSolutions announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2000 Liter scale. This contract is the first BARDA Task Order for an Ebola countermeasure awarded to Emergent under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. Under the scope of this two-year contract, the company will conduct process development, analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance. The monoclonal antibodies will be manufactured at Emergent's Bayview Campus in Baltimore, which is equipped with disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products with a quick turnaround. In 2012, it was designated by the U.S. Department of Health and Human Services as a Center for Innovation in Advanced Development and Manufacturing, which allows the company to contract with the U.S. government through task order requests for requirements such as operational readiness, development and manufacturing of CBRN products, warm base maintenance, surge manufacturing, and workforce development. In this facility, Emergent has successfully manufactured product candidates for the company's pipeline and for ongoing collaborations, including most recently the MVA-EBOZ Ebola vaccine candidate, which is now being evaluated in a Phase 1 clinical study. This task order under contract HHS0100201200004I is funded by the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

Emergent BioSolutions Inc. Enters into Long-Term Manufacturing Agreement with ProMetic Life Sciences Inc

Emergent BioSolutions Inc. announced that it has signed a strategic long-term manufacturing agreement with ProMetic Life Sciences Inc. This agreement provides ProMetic access to Emergent's cGMP FDA-licensed biopharmaceuticals facility located in Winnipeg, Manitoba, Canada. ProMetic will commence transferring its technology and manufacturing process into Emergent's Winnipeg facility as soon as possible, followed by the scale-up and manufacture by Emergent of cGMP biopharmaceuticals to enable ProMetic to pursue additional IND filings. Under the terms of this manufacturing agreement, ProMetic is obligated to purchase at least CAD 4 million of capacity in the first full contract year. The minimum order amount increases over the 15-year life of the contract. The aggregate total of the minimum fees over the life of the contract is in excess of CAD 100 million. The agreement also provides flexibility to the parties in the event services in excess of the minimum are requested by ProMetic. These services will be charged on an as-used basis.

Emergent BioSolutions, Inc. - Shareholder/Analyst Call

Annual Meeting of Stockholders


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $33.12 USD +0.355

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $21.37 USD +0.29
Bavarian Nordic A/S kr321.00 DKK +3.50
Depomed Inc $31.05 USD +0.52
Nektar Therapeutics $12.78 USD +0.445
Skyepharma PLC 280.00 GBp +1.25
View Industry Companies

Industry Analysis


Industry Average

Valuation EBS Industry Range
Price/Earnings 42.1x
Price/Sales 2.7x
Price/Book 2.3x
Price/Cash Flow 35.0x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at